Medical Director of the BC Centre for Disease Control (BCCDC) Public Health Laboratory and Medical Head of Hepatitis, and Professor of Pathology and Laboratory Medicine at UBC
I am currently the Medical Director of the BC Centre for Disease Control (BCCDC) Public Health Laboratory and Medical Head of Hepatitis. I am also a Professor of Pathology and Laboratory Medicine at the UBC. After earning my BSc and MD (1973-80) at McGill University I undertook Internal Medicine training at McGill University (1980-83). Thereafter I did a fellowship in Infectious Diseases at Stanford University (1983-86) and completed my Medical Microbiology residency at the University of Toronto (1986-87). Between 1991 and 1998, I was Section Head of Virology and Serology and an Infectious Diseases consultant at The Toronto Hospital (The University Health Network). In September 1998, I moved from Toronto to the BCCDC and the University of British Columbia. I am also an adjunct scientist with the Canadian Blood Services and member of the Canadian Blood Services Scientific and Research Advisory Committee.
My clinical research involves integration of hepatitis prevention and care services. My laboratory research involves in the application of molecular techniques to: diagnose viruses; assess correlates between infection and clinical disease; use molecular techniques to monitor antiviral efficacy; and track microbial infections for epidemiological purposes. I also have extensive clinical trials expertise and serve as a laboratory coordinator industry sponsored clinical trials.
I have been involved in various types of research domains including: hepatitis, influenza, human papillomavirus, HIV and molecular diagnostics and phylogenetics as well as the use of linked laboratory and administrative data to help understand how to measure population level health outcomes for policy making.
Below a selected list of recent publications:
1: Janjua NZ, Islam N, Kuo M, Yu A, Wong S, Butt ZA, Gilbert M, Buxton J, Chapinal N, Samji H, Chong M, Alvarez M, Wong J, Tyndall MW, Krajden M; BC Hepatitis Testers Cohort Team. Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets. Int J Drug Policy. 2018 Feb 23;55:31-39.
2: Butt ZA, Shrestha N, Wong S, Kuo M, Gesink D, Gilbert M, Wong J, Yu A, Alvarez M, Samji H, Buxton JA, Johnston JC, Cook VJ, Roth D, Consolacion T, Murti M, Hottes TS, Ogilvie G, Balshaw R, Tyndall MW, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort. A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia. PLoS One. 2017 Aug 22;12(8):e0183609.
3: Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, Butt ZA, Chong M, Cook D, Alvarez M, Darvishian M, Tyndall M, Krajden M. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study. J Viral Hepat. 2017 Aug;24(8):624-630.
4: Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, Gondara L, Franco EL, Coldman AJ, Ogilvie GS, Jang D, Chernesky M, Krajden M. Aptima HPV Assay versus Hybrid Capture(®) 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. J Clin Virol. 2017 Feb;87:23-29.
5: Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, Butt ZA, Samji H, Cook D, Yu A, Alvarez M, Tyndall M, Krajden M. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017 Mar;66(3):504-513.
6: Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, Wong J, Grebely J, Butt ZA, Samji H, Ramji A, Tyndall M, Krajden M. The Population Level Cascade of Care for
Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine. 2016 Oct;12:189-195.
7: Montoya V, Olmstead A, Tang P, Cook D, Janjua N, Grebely J, Jacka B, Poon AF, Krajden M. Deep sequencing increases hepatitis C virus phylogenetic cluster detection compared to Sanger sequencing. Infect Genet Evol. 2016 Sep;43:329-37.
8: Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer. 2015 Dec 16;15:968.
9: Olmstead AD, Joy JB, Montoya V, Luo I, Poon AF, Jacka B, Lamoury F, Applegate T, Montaner J, Khudyakov Y, Grebely J, Cook D, Harrigan PR, Krajden M. A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events. Infect Genet Evol. 2015 Jul;33:101-9.
10: Montoya V, Olmstead AD, Janjua NZ, Tang P, Grebely J, Cook D, Richard Harrigan P, Krajden M. Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: a population-level tool for incidence estimation. Hepatology. 2015 Jun;61(6):1842-50.
Last Updated: March 5, 2015